Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.62 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.62 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | GGH | Q92820 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910273 | 0.98 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL910175 | 0.98 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL910174 | 0.98 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| SCHEMBL910360 | 0.98 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| Hydrochloric Acid SCHEMBL910549 | 0.96 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| Oxalic Acid SCHEMBL910834 | 0.94 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| Succinic Acid SCHEMBL911170 | 0.94 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| Acetic Acid SCHEMBL910582 | 0.93 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| Sulfuric Acid SCHEMBL910205 | 0.91 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAGNPATGGH | |
| Maleic Acid SCHEMBL910784 | 0.90 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGNPATCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | CUTA, GLRA3, ARGLU1 | FOLH1 4099/4885NAALAD2 1692/4885RIMKLA 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.